WPWealth’s Kyntra Bio KYNB Stock Holding History

WPWealth’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-554	Closed	-$37.4K	–	61
2023 Q2	$37.4K	Hold	554	–	–	0.02%	56
2023 Q1	$258K	Hold	554	–	–	0.12%	39
2022 Q4	$222K	Buy	+554	New	+$212K	0.12%	34

Other funds holding KYNB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPWealth's KYNB Position: Q3 2023 in Review

WPWealth sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 554 shares — an estimated $37.4K sold.

WPWealth first reported a position in KYNB in Q4 2022 and held it in 3 quarters. The position peaked at $258K in Q1 2023. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

WPWealth reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
WPWealth sold 554 Kyntra Bio shares in Q3 2023, an estimated $37.4K.
WPWealth first reported a position in Kyntra Bio in Q4 2022 and held it in 3 quarters.
WPWealth's Kyntra Bio position peaked at $258K in Q1 2023.
110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on WPWealth's 13F filing for Q3 2023, filed 12 Oct 2023.